Keyphrases
Multiple Myeloma
91%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
49%
Overall Survival
46%
AL Amyloidosis
40%
Light Chain Amyloidosis
38%
Newly Diagnosed multiple Myeloma
38%
Multiple Myeloma Patients
26%
Mayo Clinic
21%
Stem Cell Transplantation
19%
Relapsed or Refractory multiple Myeloma
19%
Progression-free Survival
17%
Waldenström Macroglobulinemia
16%
Monoclonal Protein
15%
Confidence Interval
14%
Complete Response
14%
Median Overall Survival
14%
Myeloma
13%
Working Diagnosis
13%
Novel Agents
12%
Plasma Cells
12%
Bortezomib
12%
Lenalidomide
12%
Plasma Cell Leukemia
12%
Smoldering multiple Myeloma
12%
Leukemia
12%
Newly Diagnosed
11%
Amyloidosis
11%
Median Time
11%
Prognostic Significance
11%
Bone Marrow Plasma Cells
10%
Immunoglobulin Light Chain Amyloidosis
10%
High Risk
9%
Very Good Partial Response
9%
Clinical Trials
9%
Clinical Outcomes
8%
Clonal Plasma Cells
8%
Induction Therapy
8%
Plasma Cell Disorders
8%
Free Light Chains
8%
Multiparameter Flow Cytometry
8%
Hematological Response
8%
Daratumumab
7%
Light Chain
7%
Multivariate Analysis
7%
Hazard Ratio
7%
Bone Marrow
7%
Cyclophosphamide
7%
Protease Inhibitors
7%
Risk of Progression
7%
Melphalan
7%
Medicine and Dentistry
Multiple Myeloma
100%
Overall Survival
49%
AL Amyloidosis
43%
Diseases
33%
Light Chain
31%
Immunoglobulin Producing Cell
31%
Autologous Stem Cell Transplantation
27%
Amyloidosis
25%
Progression Free Survival
20%
Stem Cell Transplant
18%
Myeloma
16%
Waldenström's Macroglobulinemia
13%
Smouldering Myeloma
11%
Clinical Trial
10%
Stem Cell Therapy
10%
Plasma Cell Leukemia
9%
Flow Cytometry
9%
Dexamethasone
8%
Immunoglobulin M
8%
Hazard Ratio
7%
Melphalan
7%
Risk Stratification
7%
Monoclonal Gammopathy of Undetermined Significance
7%
Malignant Neoplasm
6%
Multivariate Analysis
6%
Fluorescence in Situ Hybridization
6%
Veterans Affairs
6%
Leukemia
6%
Lenalidomide
5%
Immunoglobulin Light Chain
5%
Cancer Registry
5%
Amyloid Protein
5%
Proteasome Inhibitor
5%
Disease
5%